{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:42:02Z","timestamp":1761597722121,"version":"build-2065373602"},"reference-count":35,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Simplivia Healthcare, Ltd."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Occupational and Environmental Hygiene"],"DOI":"10.1080\/15459624.2025.2563550","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:39:00Z","timestamp":1761597540000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A novel approach for evaluating the containment of a closed intravenous administration system for hazardous drugs"],"prefix":"10.1080","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-1395","authenticated-orcid":false,"given":"Elana A.","family":"Slutsky Smith","sequence":"first","affiliation":[{"name":"Simplivia Healthcare Ltd","place":["Kiryat Shmona, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaf","family":"Alon","sequence":"additional","affiliation":[{"name":"Simplivia Healthcare Ltd","place":["Kiryat Shmona, Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"ASSTSAS. 2008. Prevention guide safe handling of hazardous drugs. Association paritaire pour la sant\u00e9 et la s\u00e9curit\u00e9 du travail du secteur affaires sociales."},{"key":"e_1_3_5_3_1","unstructured":"ASTM. 2016. ASTM F1980:2016. Standard guide for accelerated aging of sterile medical device packages. ASTM International."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00659"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/jom.0000000000000249"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.6.354"},{"key":"e_1_3_5_7_1","unstructured":"EBN. 2019. Amendments to the carcinogens and mutagens directive on hazardous drugs and implications for change to the heathcare system in europe to ensure compliance with its requirements. European Biosafety Network."},{"key":"e_1_3_5_8_1","unstructured":"EU-OSHA. 2004. Directive 2004\/37\/EC of the European Parliament and of the Council of 29 April 2004 on the protection of workers from the risks related to exposure to carcinogens mutagens or reprotoxic substances at work. European Agency for Health and Safety at Work. https:\/\/eur-lex.europa.eu\/eli\/dir\/2004\/37\/oj\/eng"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-021-01679-x"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1188\/20.Cjon.249-255"},{"key":"e_1_3_5_11_1","unstructured":"Health and Safety at Work etc. Act. 1974. Legislation.gov.uk. https:\/\/www.legislation.gov.uk\/ukpga\/1974\/37\/contents"},{"key":"e_1_3_5_12_1","unstructured":"HSE. 2013. Control of substances hazardous to health. The control of substances hazardous to health regulations 2002 (as amended). Approved Code of Practice and guidance. L5 (Sixth edition) Health and Safety Executive."},{"key":"e_1_3_5_13_1","unstructured":"HSE. 2022. Safe handling of cytotoxic drugs in the workplace. Health and Safety Executive. https:\/\/www.hse.gov.uk\/healthservices\/safe-use-cytotoxic-drugs.htm"},{"key":"e_1_3_5_14_1","unstructured":"HSE\/MHRA. 2015. Handling cytotoxic drugs in isolators in NHS pharmacies. Health and Safety Executive and Medicines and Healthcare Products Regulatory Authority. https:\/\/www.hse.gov.uk\/pubns\/ms37.pdf"},{"key":"e_1_3_5_15_1","unstructured":"IARC. 2000. IARC Working Group on the evaluation of carcinogenic risks to humans. Some antiviral and antineoplastic drugs and other pharmaceutical agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans No 76. International Agency for Research on Cancer."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211070933"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-021-01731-w"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/nan.0000000000000142"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211030682"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/nop2.1853"},{"key":"e_1_3_5_21_1","unstructured":"The Management of Health and Safety at Work Regulations. 1999. Legislation.gov.uk. https:\/\/www.legislation.gov.uk\/uksi\/1999\/3242\/regulation\/29\/made"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2020.29.10.S15"},{"key":"e_1_3_5_23_1","unstructured":"NHS. 2018. Guidance on handling of injectable cytotoxic drugs in clinical areas in NHS hospitals in the UK. NHS Pharmaceutical Quality Assurance Committee. https:\/\/cytoprevent.eu\/wp-content\/uploads\/2021\/02\/NHS-Guidance-on-Handling-Cytotoxics-Ed-1-July-2018.pdf"},{"key":"e_1_3_5_24_1","volume-title":"Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings","author":"NIOSH","year":"2004","unstructured":"NIOSH. 2004a. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health."},{"key":"e_1_3_5_25_1","unstructured":"NIOSH. 2004b. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. In: Services DoHaH editor. https:\/\/www.cdc.gov\/niosh\/docs\/2004-165\/pdfs\/2004-165.pdf?id=10.26616\/NIOSHPUB2004165"},{"key":"e_1_3_5_26_1","first-page":"34674","article-title":"A performance test protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs. Docket CDC-2016-0090-0002. Notice of draft document for comment and review","volume":"82","author":"NIOSH","year":"2016","unstructured":"NIOSH. 2016. A performance test protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs. Docket CDC-2016-0090-0002. Notice of draft document for comment and review. Fed Reg. 82:34674.","journal-title":"Fed Reg"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1188\/19.ONF.647-648"},{"key":"e_1_3_5_28_1","unstructured":"OSHA. 2006. Hazardous drugs\u20141910.1020 access to employee exposure and medical records. Occupational Safety and Health Administration. https:\/\/www.osha.gov\/hazardous-drugs\/standards"},{"key":"e_1_3_5_29_1","unstructured":"OSHA. 2012. Occupational safety and health standards for toxic and hazardous substances 1910.1200 hazard communication. Occupational Safety and Health Administration. https:\/\/www.osha.gov\/laws-regs\/interlinking\/standards\/1910.1200\/regulations"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp180564"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/11297298211044017"},{"key":"e_1_3_5_32_1","unstructured":"Sessink PJM Sewell G Vandenbroucke J. 2016. Preventing occupational exposure to cytotoxic and other hazardous drugs. European Policy Reccomendations. European Parliament."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1188\/10.Onf.E370-e376"},{"key":"e_1_3_5_34_1","first-page":"A160","article-title":"E5PSQ-023 Litmus test method for closed system transfer device dry disconnection validation","volume":"32","author":"Slutsky Smith EA.","year":"2025","unstructured":"Slutsky Smith EA. 2025. E5PSQ-023 Litmus test method for closed system transfer device dry disconnection validation. Eur J Hosp Pharm. 32:A160\u2013A161.","journal-title":"Eur J Hosp Pharm"},{"key":"e_1_3_5_35_1","volume-title":"The United States Pharmacopeia, 39th rev, and The National Formulary","author":"USP","year":"2016","unstructured":"USP. 2016. Chapter <800>: hazardous drugs\u2014handling in healthcare settings. In: The United States Pharmacopeia, 39th rev, and The National Formulary. 34th ed. First supplement. US Pharmacopeial Convention.","edition":"34"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205263"}],"container-title":["Journal of Occupational and Environmental Hygiene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15459624.2025.2563550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:39:04Z","timestamp":1761597544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15459624.2025.2563550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":35,"alternative-id":["10.1080\/15459624.2025.2563550"],"URL":"https:\/\/doi.org\/10.1080\/15459624.2025.2563550","relation":{},"ISSN":["1545-9624","1545-9632"],"issn-type":[{"value":"1545-9624","type":"print"},{"value":"1545-9632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=uoeh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=uoeh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}